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COCHRANE REVIEWS
Cochrane Collaborative Review Group on Peripheral Vascular Diseases:
Review Abstracts
Introduction Abstracts
Abstract: Bypass surgery for chronic lower limb isch-The following abstracts are part of an ongoing series
aemiaof articles produced by the Cochrane Collaborative
G. C. Leng, D. Baker and M. DavisReview Group on Peripheral Vascular Diseases, which
Date of most recent substantive amendment: 20 April 2000is part of the Cochrane Collaboration. The reviews are
published in full on ‘The Cochrane Library’, a quarterly
electronic journal available on CD-ROM and via the
Internet. The electronic format allows Cochrane re- Background
views to accommodate new data as they become avail-
Surgical bypass of an occluded arterial segment is theable, making the library a consistently up-to-date
mainstay of treatment for patients with critical limbsource of information over time.
ischaemia. As with many surgical interventions, how-
ever, it was introduced without formal evaluation.The abstracts appearing on the Cochrane Library
are now presented in a different, simpler, less scientific
format than the abstracts presented here to permit
greater accessibility to the public. However, the sub- Objectives
stance of both versions is the same. Review abstracts on
To determine the effects of bypass surgery in patientsCochrane reviews will also be indexed on MEDLINE in
with chronic lower limb ischaemia.the near future.
If you are interested in writing a Cochrane review
or contributing to the activities of the Cochrane Peri-
Search Strategy
pheral Vascular Diseases Group, please contact: The reviewers searched the Cochrane Peripheral Vas-
cular Diseases Group trials register, EMBASE, MED-
Professor FGR Fowkes LINE, reference lists of relevant articles, and principal
Cochrane Collaborative Review Group on Peri- investigators of trials.
pheral Vascular Disease




Teviot Place All randomised controlled trials of bypass surgery
Edinburgh EH8 9AG versus control, or versus any other regimen.
Tel. +44 (0) 131 650 3220
Fax. +44 (0) 131 650 6904
Any comments or criticisms on these Cochrane re- Data Collection and Analysis
view abstracts should be made through the comments/
criticisms facility on the Cochrane Library, or by con- At least two reviewers extracted data and assessed
trial quality independently. The reviewers contactedtacting the group at the above address.
1078–5884/00/070001+03 $35.00/0  2000 Harcourt Publishers Ltd.
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investigators to obtain information or data needed for Abstract: Duration of treatment with vitamin K ant-
agonists in symptomatic venous thromboembolismthe review that could not be found in published re-
ports. Dichotomous data were analysed using the B. A. Hutten and M. H. Prins
Date of most recent substantive amendment: 12 JanuaryPeto odds ratio (OR), and continuous data with the
weighted mean difference (fixed effect and random 2000
effects models).
Background
Currently, vitamin K antagonists targeted at an INRMain Results
of 2.5 (range 2.0–3.0) are the most frequently used
secondary prophylaxis for patients with venous throm-Eight trials were identified which appeared to meet the
boembolism. However, based on the continuing riskinclusion criteria, but two were subsequently excluded.
of bleeding and uncertainty regarding the risk of re-The remaining six trials involved a total of just over
current venous thromboembolism, there is discussion700 patients, two trials comparing bypass surgery with
on the proper duration of treatment with vitamin Kangioplasty (PTA), and one with each of thrombo-
antagonists for these patients. Recently, several studiesendarterectomy, thrombolysis, exercise, and spinal
were published in which the risk and benefits ofcord stimulation. Four trials included patients with a
different durations of oral anticoagulants were com-range of disease severity (intermittent claudication
pared in patients with venous thromboembolism.and critical limb ischaemia), one was restricted to
claudicants only and another to only critical limb
ischaemia. The type of bypass procedure performed
in each trial was similar: vein grafts for distal re-
Objectivesconstructions, and synthetic prostheses for aorto-iliac
or ilio-femoral bypasses. The outcome measures
To evaluate efficacy and safety of different durationsvaried, but four of the six trials included mortality
of treatment with vitamin K antagonists in patientsand operative failure. In general the quality of the
with symptomatic venous thromboembolism.trials was good, but none was blinded because of the
nature of the intervention.
There were no clear differences between bypass Search Strategy
surgery and PTA. Mortality and amputation rates
did not differ significantly, although primary patency The reviewers sought publications through com-
was significantly higher in the bypass group after 12 puterised searches of MEDLINE and EMBASE, and
months (Peto OR 1.6, 95% confidence interval (CI) by hand-searching relevant journals, using the search
1.0, 2.6) but not after 4 years (p=0.14). Compared strategy described by the Cochrane Review Group
with thrombolysis, amputation rates were sig- on Peripheral Vascular Diseases. They also contacted
nificantly lower in the bypass group (Peto OR 0.2, colleagues.
95% CI 0.1, 0.6), but mortality rates did not differ.
Compared with thromboendarterectomy, restoration
of blood flow was significantly greater in the bypass
patients (Peto OR 9.2, 95% CI 1.7, 50.6), but mortality Selection Criteria
and amputation rates did not differ. Bypass did
not differ significantly from exercise or spinal cord Randomised clinical trials comparing different dura-
stimulation. tions of treatment with vitamin K antagonists in
patients with symptomatic venous thromboembolism.
Data Collection and AnalysisReviewers’ Conclusions
Two reviewers extracted data and assessed trial qualityEvidence for the effectiveness of bypass surgery is
limited and further large trials are required. independently.
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Main Results Reviewers’ Conclusions
Four studies with a total of exactly 1500 patients In conclusion, this meta-analysis shows that treatment
with vitamin K antagonists reduces the risk of re-were included. A consistent reduction for the risk
of recurrent events was observed during prolonged current venous thromboembolism as long as it is used.
However, the absolute risk of recurrent venous throm-treatment with vitamin K antagonists (OR 0.15; 95%
CI [0.10–0.23]) independent of the period elapsed since boembolism declines over time, while the risk for
major bleeding remains. Thus, the efficiency of vitaminthe index thrombotic event. A ‘‘rebound’’ phe-
nomenon, i.e. an excess of recurrences shortly after K antagonist administration decreases over time after
the index event.cessation of the prolonged treatment, was not observed
(OR 1.11; 95% CI [0.71–1.75]). In addition, a substantial
increase in bleeding complications was found during
the entire period after randomisation (OR 7.75; 95%
CI [1.08–55.57]).
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